May 22, 2019
The 5G Fight Is Bigger Than Huawei
A badly implemented ban would be a Pyrrhic victory at best.
The latest salvos in the Trump administration’s campaign against Huawei may prove, at best, to be a Pyrrhic victory—or, at worst, directly undermine U.S. interests and objectives. At the moment, it remains unclear how the recent executive order, which creates sweeping authorities to bar and exclude companies or technologies linked to a “foreign adversary” from the United States, and the addition of Huawei to the government blacklist known as the Entity List will be implemented in practice.
It is not too late for U.S. President Donald Trump to recalibrate toward the smarter approach needed for such a complex challenge. In the process, the U.S. government should also pursue more proactive policies that concentrate on ensuring future American competitiveness in 5G, the fifth generation of mobile networks.
Read the full article in Foreign Policy.
More from CNAS
-
Biotech Matters: Public-Private Coordination of Biotechnology
Reports
An appreciation of biotechnology’s great opportunities is, for many commentators, intimately joined with regret about a disconnect between the U.S. government and the private ...
By Richard Danzig
-
$6.6 billion TSMC deal in Arizona the latest in the CHIPS Act’s rollout
Podcast
“President Biden signed the CHIPS and Science Act just about 20 months ago, which in government time is yesterday. And they’ve hired 200 people,” said Vivek Chilukuri, a senio...
By Vivek Chilukuri
-
Response to NTIA Request for Comment: “Dual Use Foundation Artificial Intelligence Models with Widely Available Model Weights”
Commentary
In February 2024, the Department of Commerce’s National Telecommunications and Information Administration (NTIA) issued a Request for Comment (RFC) on the implications of “ope...
By Caleb Withers
-
Biotech Matters: Great Data Competition and Interoperability with Allies and Partners
Reports
Understanding and strengthening America’s biotechnology leadership requires exploring the limits of existing data relevant to the U.S. bioeconomy so that policymakers and the ...
By Michelle Holko
